Cyclacel Pharma (CYCC) Reports Q1 Loss of $0.38

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/30/2026

1. NOW
2. GOOGL
3. MSFT
4. FTNT
5. EBAY
6. TENB
7. BIIB
8. CMG
9. KLAC
10. ETSY

Go back to Cyclacel Pharma (CYCC) Reports Q1 Loss of $0.38

Cyclacel Pharmaceuticals Reports First Quarter 2018 Financial Results

May 14, 2018 4:05 PM EDT

BERKELEY HEIGHTS, N.J., May 14, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) (NASDAQ: CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today reported financial results and business highlights for the first quarter 2018.  

The Company's net loss applicable to common shareholders for the three months ended March 31, 2018 was $1.4 million.  As of March 31, 2018, cash and cash equivalents totaled $21.7 million.

Two presentations at the... More